NEW YORK, May 6, 2026, 12:02 EDT
- TransMedics tumbled over 23% as its first-quarter adjusted earnings landed short of Wall Street forecasts.
- Revenue climbed 21%. Still, profit and margins shrank—costs for logistics, R&D and expansion all crept higher.
- The 2026 sales outlook remains unchanged, leaving management under the gun to prove the growth engine will deliver.
TransMedics Group shares slid roughly 23% on Wednesday after the organ-transplant tech company disclosed a steep decline in first-quarter profit. Sales actually increased, and executives stuck to their full-year revenue outlook. By late session, the stock had dropped $22.05 to $72.88. Volume had already cleared 3.5 million shares.
This wasn’t a referendum on TransMedics’ growth—that’s still happening. The bigger issue: how pricey that growth is turning out to be, and if the company’s aircraft-driven transplant network can keep getting bigger without putting even more pressure on earnings.
TransMedics recorded $173.9 million in first-quarter revenue, a 21% jump from last year. Net income, though, slid to $7.3 million, or 20 cents per diluted share, compared with $25.7 million, or 70 cents a share, a year ago. On an adjusted basis, the company earned 30 cents a share—half the consensus estimate of 62 cents from the five analysts polled by Zacks Investment Research. Revenue also landed just short of Zacks’ projection of $175.7 million.
Gross margin at the Andover, Massachusetts-based company slipped to 58%, down from 61% a year ago, pressured by growth investments and rising supply-chain and operating costs. Operating expenses climbed to $87.9 million from $60.8 million, as research-and-development outlays and companywide investment pushed spending higher.
TransMedics stuck to its 2026 revenue forecast of $727 million to $757 million, which points to growth of 20% to 25% over 2025. Chief Executive Waleed Hassanein described a “multi-pronged growth strategy,” with focus areas spanning U.S. heart and lung programs, Europe, and a kidney initiative that’s still under development. TransMedics
TransMedics’ main offering, the Organ Care System—or OCS—lets donor organs stay viable outside the body by circulating warm, oxygen-rich blood, a departure from the old all-cold storage method. The company also runs the National OCS Program (NOP), which layers on procurement, clinical support, and transport logistics for the OCS platform.
The liver business still dominates. According to the quarterly filing, U.S. OCS liver revenue hit $139.0 million, up from $108.7 million a year ago. Heart revenue in the U.S. edged down to $25.9 million, while lung revenue dropped to $2.2 million. Altogether, U.S. OCS transplant revenue reached $167.0 million.
Chief Financial Officer Gerardo Hernandez pointed to short-term margin pressure as a result of spending before anticipated growth and new regions, but reiterated that long-term gross margins should land near 60%. Hernandez also credited stronger service revenue to increased utilization of the company’s aviation fleet.
Analysts challenged management over signs that growth could be losing steam. On the call, Stifel’s Thomas Stephan wanted to know how the company expects 2026 core revenue growth to stay strong—or even pick up—after posting more than 40% growth in early 2025, dropping to above 30% late in the year, and then easing to just over 20% in the first quarter. Hernandez pointed out that U.S. transplant volumes typically pick up as the year goes on, adding that management is still sticking with its forecast range.
Investors showed little patience. Oppenheimer downgraded TransMedics to “market perform” from “outperform” after earnings, MarketBeat noted. Analyst sentiment was divided: six Buys and six Holds on the shares. MarketBeat
The field isn’t crowded, but TransMedics isn’t alone. Its latest annual report names OrganOx and XVIVO Perfusion as rival makers of warm-perfusion systems—though each limits itself to one organ. On the cold-preservation front, Paragonix Technologies (recently acquired by Getinge) gets a mention. That’s important for TransMedics, which is working both to protect its lead in devices and to secure a bigger piece of the transport process.
Management is making a push into cold storage with CHOPS, or Controlled Hypothermic Organ Preservation System. On a call with analysts, Hassanein emphasized CHOPS is “not cannibalizing anything.” The device targets shorter heart and lung transport runs that currently rely on static cold storage, he said. But before any commercial discussions, the company still needs to complete the FDA study process. The Motley Fool
Execution looms as the main risk here. In its latest quarterly filing, TransMedics pointed to its reliance on both the OCS and NOP, flagged uncertainty around clinical trial outcomes and timing, and called out an ongoing material weakness in tracking inventory. The company also cited heavy dependence on a handful of suppliers and sterilization partners. Aviation headaches aren’t off the table either—FAA requirements, a tight pool of pilots, and potential flight disruptions all made the list.
